Just looking at some of NEU's biotech peers (noting this a very simplistic back of the envelope comparison):
Mesoblast (MSB): MC $1.7 Billion, EV $1.5B (MC less $280M cash), 280M shares on issue, 9 products/target markets (stem cell?) in pipeline but all at Phase II i.e. still a few hoops to jump thru b4 commercialisation.
Prima Biomed (PRR): MC $184 Million, EV $180 (MC less $4M cash), 700M shares on issue, cell therapies targeting a number of cancers, at the Phase II stage.
NEU: MC $7 Million, EV $5M (MC less $2M cash), 500M shares, 2 products (one being the 'sexy' TBI market) nearing? Phase II completion.
What valuation NEU?, should they overcome Phase II hurdles?
NB - Prima Biomed and NEU have similar Springtree convertible note arrangements...
- Forums
- ASX - By Stock
- NEU
- neu comparison vs other biotechs
neu comparison vs other biotechs
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.51 |
Change
-0.350(1.76%) |
Mkt cap ! $2.494B |
Open | High | Low | Value | Volume |
$19.70 | $19.77 | $19.28 | $7.031M | 361.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 1234 | $19.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.51 | 13 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 1073 | 19.490 |
6 | 292 | 19.480 |
8 | 519 | 19.470 |
10 | 951 | 19.460 |
7 | 965 | 19.450 |
Price($) | Vol. | No. |
---|---|---|
19.510 | 23 | 5 |
19.520 | 140 | 6 |
19.530 | 278 | 4 |
19.540 | 324 | 4 |
19.550 | 228 | 3 |
Last trade - 12.57pm 30/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online